Briggs W. Morrison

Briggs W. Morrison received his B.S. in biology from Georgetown University, his M.D. from the University of Connecticut Medical School, completed residency training in Internal Medicine at the Massachusetts General Hospital, and completed a fellowship in Medical Oncology at the Dana-Farber Cancer Institute. He did post-docs with Philip Leder at Harvard Medical School, and Lee Nadler at the Dana-Farber Cancer Institute. He joined Merck & Co., Inc. in 1995, was appointed Head of Clinical Development at Pfizer in 2007, and became the Head of Global Medicines Development and Chief Medical Officer at AstraZeneca in 2012. He is currently the CEO of Syndax Pharmaceuticals.

Dr. Morrison has overseen the development of numerous biopharmaceutical products in multiple therapeutic areas, from First-In-Human trials through to global regulatory approvals. He is currently a Board member of private companies Oncorus and Repare Therapeutics, and is an advisor to a number of other private biotechnology companies. In addition, Dr. Morrison is a Board member of the Alliance for Clinical Research Excellence and Safety (ACRES), a non-profit organization dedicated to optimizing the global clinical research system.